A message from Alan W. Partin, M.D., Ph.D. in DISCOVERY 2021

Partnerships with donors make discoveries possible. Thank you to those who support The Patrick C. Walsh Prostate Cancer Research Fund.

This novel therapy slowed the growth in 93 percent of mice with prostate cancer, and 53 percent of mice with pancreatic cancer.

The test looks for proteins in the urine that are made by clinically significant prostate cancer.

Researchers developed a study to evaluate SelectMDx’s ability to identify men on active surveillance who are likely to experience upgrading.

What’s the best course of treatment for men with localized prostate cancer? That’s actually a trick question.

Innovating to discover the nerve-sparing radical prostatectomy

Stoianovici’s lab has built a prototype of the new probe, and used it in preclinical tests – that were so promising, the FDA has approved the device for clinical trials.

A new da Vinci robotic system involves only one small incision, near the patient’s navel. How does it compare to the standard robotic prostatectomy?

Researchers working to identify the specific nerves out of these bundles that are involved in erection.

Researcher are investigating a promising new target: a molecule called B7-H3

Understanding Why African American Men Are at Higher Risk of Aggressive Cancer

“By inhibiting miR-21 in localized prostate cancers, we could potentially reduce the amount of radiation needed for primary or salvage radiation therapy”

PyL is now another step closer to FDA approval.

Phuoc Tran, M.D., Ph.D., is now looking for a better early warning test to detect the early spread of prostate cancer.

Could timing make a difference with drugs that target the androgen receptor, combined with radiation and other treatments?

The Brady team is investigating whether these cancers are uniquely sensitive to therapies that target tumor blood vessels.

B cells play a vital role in the immune response against cancer

Small cell neuroendocrine bladder carcinoma has a lot in common with small cell neuroendocrine lung cancer, and this may lead to new strategies for treatment.

Who needs surgical removal of the bladder (radical cystectomy)? And who doesn’t need it?

Kates and colleagues have begun investigating a combination of two chemotherapy drugs

Meet our two new faculty form a multidisciplinary and translational kidney cancer group.

“We have identified candidate drug targets that have been explored in other cancer types, but have yet to be evaluated in ccRCC.”

Extracting these vesicles from the blood and urine could make it possible to diagnose kidney cancer noninvasively.

Finding new potential biomarkers and targets for treating kidney cancer.

“Sometimes the best course is to do nothing,” says urologist Phillip Pierorazio, M.D., Director of the Testicular Cancer Program.

This study is the first to link immunotherapy for cancer with reduced sperm-producing cells.

New tests could identify who will benefit from chemotherapy, and spare those who will not.